Paloma Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-2,468
| Closed | -$240K | – | 1365 |
|
|
2021
Q2 | $240K | Buy |
+2,468
| New | +$240K | ﹤0.01% | 1216 |
|
|
2019
Q4 | – | Sell |
-12,354
| Closed | -$1.11M | – | 1994 |
|
|
2019
Q3 | $1.11M | Buy |
+12,354
| New | +$1.11M | 0.02% | 507 |
|
|
2019
Q2 | – | Sell |
-11,680
| Closed | -$1.03M | – | 1696 |
|
|
2019
Q1 | $1.03M | Buy |
+11,680
| New | +$1.03M | 0.03% | 484 |
|
|
2018
Q4 | – | Sell |
-24,345
| Closed | -$2.99M | – | 1270 |
|
|
2018
Q3 | $2.99M | Buy |
+24,345
| New | +$2.99M | 0.05% | 193 |
|
|
2018
Q2 | – | Sell |
-14,713
| Closed | -$1.22M | – | 1511 |
|
|
2018
Q1 | $1.22M | Sell |
14,713
-19,432
| -57% | -$1.61M | 0.02% | 506 |
|
|
2017
Q4 | $2.65M | Buy |
34,145
+8,557
| +33% | +$664K | 0.04% | 204 |
|
|
2017
Q3 | $1.57M | Buy |
+25,588
| New | +$1.57M | 0.02% | 443 |
|
|
2017
Q2 | – | Sell |
-39,539
| Closed | -$1.71M | – | 1780 |
|
|
2017
Q1 | $1.71M | Sell |
39,539
-445
| -1% | -$19.3K | 0.02% | 523 |
|
|
2016
Q4 | $1.55M | Buy |
39,984
+19,708
| +97% | +$763K | 0.02% | 527 |
|
|
2016
Q3 | $1.03M | Sell |
20,276
-131,447
| -87% | -$6.66M | 0.01% | 597 |
|
|
2016
Q2 | $6.9M | Buy |
151,723
+123,023
| +429% | +$5.59M | 0.08% | 105 |
|
|
2016
Q1 | $1.14M | Buy |
+28,700
| New | +$1.14M | 0.02% | 517 |
|
|
2015
Q4 | – | Sell |
-8,949
| Closed | -$356K | – | 1492 |
|
|
2015
Q3 | $356K | Buy |
+8,949
| New | +$356K | 0.01% | 895 |
|
|
2014
Q4 | – | Sell |
-18,690
| Closed | -$293K | – | 1187 |
|
|
2014
Q3 | $293K | Buy |
+18,690
| New | +$293K | 0.01% | 657 |
|
|
2013
Q3 | – | Sell |
-63,877
| Closed | -$855K | – | 1082 |
|
|
2013
Q2 | $855K | Buy |
+63,877
| New | +$855K | 0.05% | 285 |
|